Загрузка...
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...
Сохранить в:
| Опубликовано в: : | Rheumatol Int |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7353833/ https://ncbi.nlm.nih.gov/pubmed/32654078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-020-04629-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|